Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risankizumab: Mechanism of action, clinical and translational science

1 Jan 2024

Abstract excerpt

Risankizumab is a high-affinity neutralizing anti-interleukin (IL)-23 monoclonal antibody marketed in over 40 countries across the globe to treat several inflammatory diseases, such as plaque psoriasis (PsO), psoriatic arthritis (PsA), and Crohn's disease (CD). This paper reviews the regulatory approval, mechanism of action, pharmacokinetics (PKs)/pharmacodynamics, immunogenicity, and clinical efficacy and safety...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Inflammatory Bowel Disease
Share to Psoriasis: Treatment and Pathogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38266061
DOI: 10.1111/cts.13706

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risankizumab: Mechanism of action, clinical and translational sciencePMID 38266061Read ↗

The regulatory mechanism and potential application of IL-23 in autoimmune diseasesSemantic proximity Read ↗

Upadacitinib: Mechanism of action, clinical, and translational scienceSemantic proximity Read ↗

IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.Semantic proximity Read ↗

The Oncology: Disease Modifying Anti-Rheumatic Drug Interface: A Cross-Specialty ReviewSemantic proximity Read ↗

Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic ReviewSemantic proximity Read ↗

Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic EffectsSemantic proximity Read ↗

Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseasesSemantic proximity Read ↗

Baseline Clinical, Hormonal and Molecular Markers Associated with Clinical Response to IL-23 Antagonism in Hidradenitis Suppurativa: A Prospective Cohort StudySemantic proximity Read ↗

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 TreatmentSemantic proximity Read ↗

Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus ErythematosusSemantic proximity Read ↗

Insights into IL-23 biology: From structure to functionSemantic proximity Read ↗

Risankizumab and risk of new‑onset depressive episodes and generalized anxiety disorder among adults with psoriasis: a propensity‑matched, real‑world cohort study across 107 health systemsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.